Table 1 Baseline patient characteristics.
Not achieving hematologic complete response (n = 215)a | |||||
|---|---|---|---|---|---|
Total cohort (n = 305) | Complete hematologic response (n = 90) | iFLC < 20 mg/L (n = 63) | dFLC < 10 mg/L (n = 65) | normal FLCR (n = 86) | |
Median age at time of SCT, range | 57 (26–77) | 56 (26–70) | 57 (36–74) | 58 (35–74) | 58 (35–77) |
Females, n (%) | 115 (38) | 36 (40) | 34 (55) | 31 (48) | 31 (36) |
Organ involvement | |||||
Cardiac, n (%) | 160 (53) | 46 (51) | 21 (34) | 26 (41) | 37 (44) |
Renal, n (%) | 240 (79) | 74 (82) | 49 (79) | 53 (83) | 78 (92) |
Liver, n (%) | 37 (12) | 17 (19) | 6 (10) | 8 (13) | 12 (14) |
Peripheral nervous system, n (%) | 32 (11) | 14 (16) | 4 (7) | 5 (8) | 4 (5) |
Autonomic nervous system, n (%) | 51 (17) | 16 (18) | 10 (16) | 14 (22) | 15 (18) |
Boston University Cardiac Stageb | |||||
Stage I, n (%) | 82 (27) | 22 (24) | 26 (42) | 26 (41) | 24 (28) |
Stage II, n (%) | 68 (22) | 19 (21) | 11 (18) | 11 (17) | 15 (18) |
Stage III, n (%) | 26 (9) | 7 (8) | 5 (8) | 5 (8) | 8 (9) |
Stage IIIb, n (%) | 8 (3) | 3 (3) | 0 | 2 (3) | 3 (4) |
Renal stagec | |||||
Stage I, n (%) | 143 (47) | 33 (37) | 29 (47) | 29 (45) | 30 (35) |
Stage II, n (%) | 117 (38) | 37 (41) | 26 (42) | 27 (42) | 36 (42) |
Stage III, n (%) | 42 (14) | 18 (21) | 8 (13) | 9 (14) | 18 (21) |
Hematologic parameters | |||||
Median dFLC, mg/L (range)d | 79 (0–7094) | 60 (0.3–2282) | 28 (0.1–879) | 28 (0.1–771) | 36 (0.1–1157) |
Bone marrow plasma cell % (range) | 10 (0–50) | 10 (0–50) | 10 (0–30) | 10 (0–30) | 10 (0–30) |
Melphalan dose | |||||
100 mg/m2, n (%) | 13 (4) | 2 (2) | 2 (3) | 4 (6) | 7 (8) |
140 mg/m2, n (%) | 103 (34) | 27 (30) | 17 (27) | 21 (33) | 32 (37) |
200 mg/m2, n (%) | 189 (62) | 61 (68) | 44 (71) | 40 (63) | 47 (55) |
